Advertisement

Topics

Novartis' Afinitor, Pfizer's Sutent gain NICE backing for neuroendocrine tumors

06:16 EDT 30 Jun 2017 | SmartBrief

The National Institute for Health and Care Excellence has recommended the use of Pfizer's Sutent, or sunitinib malate, as a t -More

Original Article: Novartis' Afinitor, Pfizer's Sutent gain NICE backing for neuroendocrine tumors

NEXT ARTICLE

More From BioPortfolio on "Novartis' Afinitor, Pfizer's Sutent gain NICE backing for neuroendocrine tumors"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pfizer
Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...